

Preliminary proposal September 2018



INTRODUCTION

Our mission is to extend people's healthspan and lifespan

Our vision to become a global leader in changing the practice of healthcare

Short-term goal: navigate clients, who desire optimal health, to achieve a long active life using evidence-based, anti-aging algorithms, and practices by A4M (American Academy of Anti Aging Medicine)

Long-term goal: Build the leading AI (artificial intelligence) platform for supporting doctors and patients to make better decisions in 5P (Predictive, Preventive, Personalized, Participatory, Proven) and anti-aging medicine

Investment requirements: 6 million seed financing for R&D. We will open Series A for product sales and marketing once R&D is completed and benchmarks achieved

AITERNIS

WHY NOW



Medical data is already being collected. We have the AI processing power to structure the data and give meaningful information back to the user

Watson is costly and relies on expensive data. We will use our customers data to create data efficiency

Other programs in health care are focused on traditional practices. We will be the first company to offer the most advanced options

WE KNOW, HOW!



The A4M association has a set of evidence-based algorithms of anti-aging therapies that work

Our team of highly qualified professionals agree to work together with their team and put these algorithms into our application

It is the first anti-aging project to distribute anti-aging information to people, using the power of mobile technologies

PEOPLE NEED IT!

Demands in anti-aging options are growing exponentially

Traditional healthcare does not support the needs of healthy people on their road to a long fulfilling life

PROBLEM



PEOPLE AROUND THE WORLD ARE GROWING OLDER—AND LIVING LONGER

In 2015, 8.5 percent (617 million) of the world's population was age 65 or older. That number is expected to grow to 17 percent (1.6 billion) by 2050, according to An Aging World: 2015



PEOPLE WANT TO LIVE LONG AND STAY HEALTHY

Families, governments, and insurance companies increase their spending on the treatments of age related diseases as the population grows older. People don't want to just live longer, they want to stay healthy longer



A SOLUTION CALLS FOR A COMPLEX SYSTEMS APPROACH

Most doctors today use outdated techniques and do not keep up with advancements in medicine. We help doctors access current scientific data that can be used to help them make better decisions and create better outcomes to increase the healthspan and lifespan of their patients



DR ROBERT GOLDMAN Co-founder

Dr. Goldman, holds two Physician & Surgeon Medical Degrees and two Medical Doctorates and has served as a Senior Fellow at the Lincoln Filene Center, Tufts University and as an

Affiliate at the Philosophy of Education Research Center, Graduate School of Education, Harvard University. He co-founded and served as Chairman of the Board of Life Science Holdings and Organ Inc. biomedical R&D companies with over 150 medical patents under development in the areas of brain resuscitation, trauma and emergency medicine, organ transplant and blood preservation technologies. These led to the formation of Organ Recovery Systems Inc. and then LifeLine Scientific Inc, a Public Company, which became a world leader in organ preservation and transport. He has overseen cooperative research agreement development programs in conjunction with the American National Red Cross, NASA, the Department of Defense, and the FDA's Center for Devices & Radiological Health



DR AUBREY
DE GREY
Co-founder

Dr. Aubrey de Grey is a biomedical gerontologist based in Cambridge, UK and Mountain View, California, USA, and is the Chief Science Officer of SENS Research Founda-

tion, a California- based 501(c)(3) charity dedicated to combating the aging process. He is also Editor-in-Chief of Rejuvenation Research, the world's highest-impact peer-reviewed journal focused on intervention in aging. He received his BA and Ph.D. from the University of Cambridge in 1985 and 2000 respectively. His original field was computer science, and he switched to biogerontology in the mid-1990s. His research interests encompass the characterisation of all the accumulating and eventually pathogenic molecular and cellular side-effects of metabolism ("damage") that constitute mammalian aging and the design of interventions to repair and/or obviate that damage



YURIY ORESHIN Co-founder, CEO, Product Architect

Yuriy's goal in life is to accelerate medical research and improve patient care to significantly extend human lifespan and healthspan. Prior to founding Aiternis Yuriy co-founded Alvansa

pharmaceutical holding with a total investment of \$200M. Together with his Partners he raised \$58M in PIPE for Affitech, NASDAQ OMX Copenhagen listed company focused on antibody therapeutics research for cancer treatment. Yuriy served as the CEO of subsidiary of CureLab Oncology Inc. a US based oncology gene therapy drug development company. He also worked as Director of Licensing and Business Development at the Human Stem Cell Institute - top 5 company in the world that registered and brought to market gene therapy drug. Graduated from the Darla Moore School of Business, University of South Carolina. Studying Deep Learning taught by Andrew Ng Co-founder, Coursera; Adjunct Professor, Stanford University; formerly head of Baidu Al Group/Google Brain



MIKHAIL PLISS Co-founder, CTO & CIO

Mikhail worked for Microsoft, Public Sector, Healthcare; Oracle Netherlands BV, Public Sector, Healthcare.

Philips Healthcare, Healthcare Transforma-

tion Services; as well as participated in Mckinsey and Company projects.

25+ years of professional experience in IT.

16+ years management C-level or Senior Consulting level, leadership skills and team management. in process and project-based organizations.

7+ years in IT in Healthcare and social sphere.

6+ years in successful sales in strategic, management and IT consulting in healthcare and social sphere



DR RONALD KLATZ Co-founder

Dr. Ronald Klatz, is a physician, medical scientist, futurist, and innovator. He coined the term "anti-aging medicine" and is recognized as a leading authority in

the new clinical science of anti- aging medicine. Dr. Klatz is the physician founder and President of the American Academy of Anti-Aging Medicine. In 1984, Dr. Klatz was a pioneer in the clinical specialty of preventative medicine: as a principal founder of the National Academy of Sports Medicine and researcher into elite human performance and physiology. Dr. Klatz is a best-selling author, and is columnist or Senior Medical Editor to several international medical journals



DR EVGENIY
KOVALEV
Co-founder,
Medical Director

Member of the expert council on healthcare in the State Duma of the Russian Federation. From 2009 - 2013 was one of the people in

charge of the entire Sports Medicine in the country for the Ministry of Health of Russia. Anti-age medicine expert (formulates anti-age protocols and therapeutic interventions plan, regularly attends international congresses on biogerontology and gerontopsychology. Graduated from Koc University (Turkey). Regularly reads lectures in Turkey, Austria and Greece



DR MARINA MELGUNOVA Co- Founder, COO, R&D

Majored in general therapy and received postgraduate specialization in neurology. Received PhD in medical sciences. Received clinical psy-


chology degree. Studied Management in Healthcare in the British Open University. Organized medical services at ROSNO (leading Russian insurance company, now Allianz). Worked as a CEO of private hospital Hospital WEST, based in the 1st Clinical Hospital Volynskaya of the Department for Presidential Affairs (of the Russian Federation). Worked as the Head of the international cooperation department of MEDSI Group - largest private healthcare group of hospitals in CIS. Organized rehabilitation and treatment abroad at SOGAZ - second largest insurance company in CIS



ELIZABETH PARRISHCo- Founder, PR, IR

Elizabeth Parrish is a humanitarian, entrepreneur, innovator, and a leading voice for genetic cures. She is the founder and CEO of BioViva, Washington-based platform for ad-

vanced gene and cell therapeutics. BioViva in collaboration with Integrated Health Systems Ltd (IHS) examine data of patients who are given access to consensual gene and cell therapies worldwide and connect researchers with medical doctors to collect data and show evidence if some of the most promising therapies in regenerative medicine are working in patients. Founding member of the International Longevity Alliance (ILA). She is an affiliated member of the Complex Biological Systems Alliance (CBSA), which is a unique platform for Mensa based, highly gifted persons who advance science



OUR GOAL

Lifespan increase, achieved by regulators in the areas of ecology, finance, law, and healthcare innovations does not by itself lead to a healthspan increase. At about 40-50 years of age people begin to accumulate a set of chronic diseases due to a large number of factors (medical term «comorbidity»).


To increase healthspan and lifespan we need to utilize a systems approach of 5P medicine.

The main aspects of this approach include a combination of healthcare innovations, IT and a patients active participation towards their own health

LIFESPAN INCREASE

Components of all government and private programs of **healthspan** increase over time:

- Healthy lifestyle and physical exercise
- Primary healthcare support
- Anti-aging activities and health activation
- Regenerative medicine
- Targeted therapies for treatment of chronic disease



5P MEDICINE COMPONENTS

Molecular biology

Sequencing technologies

Medical technologies

Big data

Processing capacity


Connectivity technologies

CLINICAL PROCEDURES

INFORMATION TECHNOLOGY

Structured. stratified and relevant approaches for **5P health care**:

Personalized Participatory Preventive Predictive Proven



To increase the healthspan of an individual it is necessary to develop personal recommendations based on each person's health data, genetic tests, and family medical history. This information has to be processed and supplied to a patient in an easy to read and understand format that will motivate him to follow recommendations

AITERNIS OFFERING

AITERNIS™ OFFERS ITS INPUT INTO SOLVING THE PROBLEM OF HEALTHSPAN EXTENSION



Patient downloads mobile app

FRONT-END

App and chatbots are the external part of the system

AITERNIS

BACK-END

Produces personalized recommendations from analytical system of personalized recommendations

MED AND SCIENCE OFFICE

Recommendations are developed by doctors and scientists, analysts work on algorithmization and personalization of recommendations

HEALTH •COACHES

Doctors following methodologies develop personalised recommendations

LABS

Selected labs get certified to conduct required tests according to A4M methodology

A4M ANTI-AGING MEDICINE ASSO-CIATION AND DOCTOR COMMUNITY

Association recommends methods based on evidence based medicine

ECOSYSTEM FUNCTIONALITY LOGIC

FRONT-END

App functions: convenient communications with the patients, compatible with equipment for real time and home health monitoring, integration with the calendar for reminders, integration with messengers and social networks for communications with chat bots, geoposition of labs, and telemedicine for personal assistants

BACK-END

Management of the personal profiles of patients, protection of personal medical data, system of selection of recommendations, system of scheduling, database of knowledge for the patients, database of knowledge for the doctors, online education, certified labs database, database of certified doctors, marketplace for certified nutraceuticals, therapeutics etc.

MED AND SCIENCE OFFICE

Management of evidence based anti-aging medical protocols and methods, recruitment of certified doctor associations and labs, algorithmization of recommendations in the context of selected methods

A4M

Approval and certification of methods, education for health coaches and their certification

HEALTH COACHES

Personalised patient management and service via a mobile app, monitoring of health indicators, connection with the patients via telemedicine technologies, in person patient visits, health and wellness events for groups of patients

LABS

Test panels for diagnostics with approved and certified A4M methods

WORK PLAN:

BUSINESS AND RECRUITMENT DEVELOPMENT **PATIENT FUNCTIONAL** JORNEY AND SETUP **AND PILOT** REQUIREMENT Description of full algo-Business and functional Hire development team, Product development rithm of how ecosystem and testing, business requirements, UX design select test region for works for several types for pilot region model tuning in the test product testing, create a of healthy individuals acmarket area detailed business plan, cording to 3-5 anti-agfundraising and back ing methodologies, algooffice setup rithmization, creation of the medical part of the business and functional requirements 1.5 years 0.5 years 0.5 years 0.5 years

STAGE 1. PATIENT'S JOURNEY

DOCTORS AND ANALYSTS WORK ON THE DEVELOPMENT OF MEDICAL LIFESPAN TECHNOLOGIES ALGORITHMS AND HEALTHSPAN BUSINESS PROCESSES



Expected result - a document that will allow IT to give recommendations in a fully automated mode for 2-3 types of patients who selected 3 aging theories



POSITIONING

LIVE LIKE THIS HEALTHCARE MANAGMENT SYSTEM

Brand essence – ensuring a high quality of life at any age

We can not prevent aging. What we do is help an individual to stay active, healthy, and to preserve quality of life using both medical and non-medical methods

We will position ourselves as an internationally recognized health management AI system of 5P and anti-aging medicine

NEXT STEPS



- Investor response on continued interest in investment evaluation
- Letter of Intent negotiation/finalization with team and opinion leaders
- Parallel investment evaluation of Aiternis team and strategy
- Aiternis finalize investment proposal based on financials and product info from team and opinion leaders
- Investment decision made by investor
- Investment into Aiternis new-co that will be formed and operated in the location selected by investor and implementation of Aiternis product development and launch plan

